Ipilimumab and Nivolumab as First-Line Treatment of Patients with Renal Cell Carcinoma: The Evidence to Date

Immunotherapy has revolutionized the management of metastatic renal cell carcinoma with four checkpoint inhibitors (nivolumab, ipilimumab, avelumab, and pembrolizumab) approved either as monotherapy or as combination therapy. The use of ipilimumab and nivolumab for treatment-naïve, intermediate to p...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheng, Iris Y, Ornstein, Moshe C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320748/
https://www.ncbi.nlm.nih.gov/pubmed/32606975
http://dx.doi.org/10.2147/CMAR.S202017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320748/
https://www.ncbi.nlm.nih.gov/pubmed/32606975
http://dx.doi.org/10.2147/CMAR.S202017

Ejemplares similares